Mylan, Lupin Prevail In Generic-Seasonique Patent Suit

Law360, New York (July 2, 2012, 6:07 PM EDT) -- Mylan Inc. and Lupin Ltd. scored a victory Friday in a Teva Women's Health Inc. lawsuit over efforts to market generic versions of Teva's oral contraceptive Seasonique, when the sole patent claim being asserted by Teva was deemed invalid.

U.S. District Judge Peter G. Sheridan issued a 47-page opinion that said the claim at issue was invalid and signed off on an order dismissing the case with prejudice. Mylan and Lupin previously stipulated that their abbreviated new drug applications for generic Seasonique would infringe that claim,...
To view the full article, register now.

UK Financial Services

UK Financial Services

Read Our Latest UK Financial Services Coverage

Financial Services Law360 UK provides breaking news and analysis on the financial sector. Coverage includes UK and European Union policy, enforcement, and litigation involving banks, asset management firms, and other financial services organizations.